Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTU7ZMG)

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

3 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[2]
Carfilzomib	DM48K0X	Multiple myeloma	2A83	Approved	[1]
MLN9708	DMCMETN	Amyloidosis	5D00	Approved	[3]
------------------------------------------------------------------------------------

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marizomib	DME9QGW	Glioblastoma of brain	2A00.00	Phase 3	[4]
Delanzomib	DMX4DQH	Multiple myeloma	2A83	Phase 2	[5]
Oprozomib	DM16RIC	Hodgkin lymphoma	2B30	Phase 2	[6]
GSK3494245	DMSMQGL	Visceral leishmaniasis	1F54.0	Phase 1	[7]
------------------------------------------------------------------------------------

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PS-519	DMI0WHC	Ischemia-reperfusion injury	DB98.B	Terminated	[8]
------------------------------------------------------------------------------------

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MG-101	DM3RUT8	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------

References

1	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80.
4	Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.
5	Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70.
6	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15.
7	Clinical pipeline report, company report or official report of GlaxoSmithKline
8	Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in... Neurotox Res. 2003;5(7):505-14.
9	Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study.J Mol Model.2009 Dec;15(12):1481-90.